Core Points - NovaBay Pharmaceuticals has regained compliance with the NYSE American's continued listing standards as of October 20, 2025 [1][4] - The company was previously notified of non-compliance on April 18, 2024, and May 28, 2024, due to insufficient stockholders' equity [2] - NovaBay raised approximately $6.0 million through the issuance of pre-funded warrants and an additional $2.15 million from the sale of Series E non-voting convertible preferred stock, bringing its stockholders' equity above the required $6 million [3] Company Background - NovaBay Pharmaceuticals focuses on the development and sale of scientifically created and clinically proven products in eyecare, wound care, and skin care [5]

Company Overview - Turn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing next-generation dermatology, wound care, and anti-infective therapies [5] - The company is based in California and recently commenced trading on the Nasdaq Capital Market [2] Market Performance - Turn Therapeutics' shares surged by 134.29% after the market closed on Wednesday, reaching a closing price of $16.40 [1] - During regular trading on the same day, TTRX shares fell by 26.47%, closing at $7.00 [5] Nasdaq Listing - The Securities and Exchange Commission (SEC) declared Turn's registration statement on Form S-1 effective on September 30 [2] - The Nasdaq Exchange welcomed Turn Therapeutics on social media, highlighting its innovative approach in pharmaceutical technologies [2] Leadership Insights - Bradley Burnham, the founder and CEO, emphasized the company's lean operating model, stating it was "built on a shoestring, with an absolute disdain for waste" [3] Closing Bell Ceremony - Turn Therapeutics participated in the closing bell ceremony at Nasdaq's MarketSite in New York, which was broadcast live [4]